The Impact of the 340B Program on Drug Prices Charged by Manufacturers and Covered Entities
This week, our In Focus highlights a Leavitt Partners white paper, The Impact of the 340B Program on Drug Prices Charged by Manufacturers and Covered Entities, published in November 2022.
Every Wednesday, HMA publishes the Weekly Roundup, an information-packed resource that will keep you updated on industry news, trends in state health policy throughout the nation, and more.
